Advanced

Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B : a PedNet study

Male, Christoph ; Andersson, Nadine G ; Rafowicz, Anne ; Liesner, Ri ; Kurnik, Karin ; Fischer, Kathelijn ; Platokouki, Helen ; Santagostino, Elena ; Chambost, Hervé and Nolan, Beatrice , et al. (2020) In Haematologica
Abstract

The incidence of FIX inhibitors in severe hemophilia B (SHB) is not well defined. Frequencies of 3-5% have been reported but most studies to date were small, including patients with different severities, and without prospective follow-up for inhibitor incidence. Study objective was to investigate inhibitor incidence in patients with SHB followed up to 500 exposure days (ED), the frequency of allergic reactions, and the relationship with genotypes. Consecutive previously untreated patients (PUPs) with SHB enrolled into the PedNet cohort were included. Detailed data was collected for the first 50 ED, followed by annual collection of inhibitor status and allergic reactions. Presence of inhibitors was defined by at least two consecutive... (More)

The incidence of FIX inhibitors in severe hemophilia B (SHB) is not well defined. Frequencies of 3-5% have been reported but most studies to date were small, including patients with different severities, and without prospective follow-up for inhibitor incidence. Study objective was to investigate inhibitor incidence in patients with SHB followed up to 500 exposure days (ED), the frequency of allergic reactions, and the relationship with genotypes. Consecutive previously untreated patients (PUPs) with SHB enrolled into the PedNet cohort were included. Detailed data was collected for the first 50 ED, followed by annual collection of inhibitor status and allergic reactions. Presence of inhibitors was defined by at least two consecutive positive samples. Additionally, data on factor IX gene mutation was collected. 154 PUPs with SHB were included; 75% were followed until 75 ED, and 43% until 500 ED. Inhibitors developed in 14 patients (7 high-titre). Median number of ED at inhibitor manifestation was 11 (IQR 6.5-36.5). Cumulative inhibitor incidence was 9.3% (95%CI 4.4-14.1) at 75 ED, and 10.2% (5.1-15.3) at 500 ED. Allergic reactions occurred in 4 (28.6%) inhibitor patients. Missense mutations were most frequent (46.8%) overall but not associated with inhibitors. Nonsense mutations and deletions with large structural changes comprised all mutations among inhibitor patients and were associated with an inhibitor risk of 26.9% and 33.3%, respectively. In an unselected, well-defined cohort of PUPs with SHB, cumulative inhibitor incidence was 10.2% at 500 ED. Nonsense mutations and large deletions were strongly associated with the risk of inhibitor development. The PedNet Registry is registered at clinicaltrials.gov; identifier: NCT02979119.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
Haematologica
publisher
Ferrata Storti Foundation
external identifiers
  • pmid:31919092
ISSN
1592-8721
DOI
10.3324/haematol.2019.239160
language
English
LU publication?
yes
additional info
Copyright © 2020, Ferrata Storti Foundation.
id
3b06ff71-d7df-4bf6-8bc6-bac792143fd6
date added to LUP
2020-01-16 19:13:19
date last changed
2020-01-17 13:21:13
@article{3b06ff71-d7df-4bf6-8bc6-bac792143fd6,
  abstract     = {<p>The incidence of FIX inhibitors in severe hemophilia B (SHB) is not well defined. Frequencies of 3-5% have been reported but most studies to date were small, including patients with different severities, and without prospective follow-up for inhibitor incidence. Study objective was to investigate inhibitor incidence in patients with SHB followed up to 500 exposure days (ED), the frequency of allergic reactions, and the relationship with genotypes. Consecutive previously untreated patients (PUPs) with SHB enrolled into the PedNet cohort were included. Detailed data was collected for the first 50 ED, followed by annual collection of inhibitor status and allergic reactions. Presence of inhibitors was defined by at least two consecutive positive samples. Additionally, data on factor IX gene mutation was collected. 154 PUPs with SHB were included; 75% were followed until 75 ED, and 43% until 500 ED. Inhibitors developed in 14 patients (7 high-titre). Median number of ED at inhibitor manifestation was 11 (IQR 6.5-36.5). Cumulative inhibitor incidence was 9.3% (95%CI 4.4-14.1) at 75 ED, and 10.2% (5.1-15.3) at 500 ED. Allergic reactions occurred in 4 (28.6%) inhibitor patients. Missense mutations were most frequent (46.8%) overall but not associated with inhibitors. Nonsense mutations and deletions with large structural changes comprised all mutations among inhibitor patients and were associated with an inhibitor risk of 26.9% and 33.3%, respectively. In an unselected, well-defined cohort of PUPs with SHB, cumulative inhibitor incidence was 10.2% at 500 ED. Nonsense mutations and large deletions were strongly associated with the risk of inhibitor development. The PedNet Registry is registered at clinicaltrials.gov; identifier: NCT02979119.</p>},
  author       = {Male, Christoph and Andersson, Nadine G and Rafowicz, Anne and Liesner, Ri and Kurnik, Karin and Fischer, Kathelijn and Platokouki, Helen and Santagostino, Elena and Chambost, Hervé and Nolan, Beatrice and Königs, Christoph and Kenet, Gili and Ljung, Rolf and van den Berg, Marijke},
  issn         = {1592-8721},
  language     = {eng},
  month        = {01},
  publisher    = {Ferrata Storti Foundation},
  series       = {Haematologica},
  title        = {Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B : a PedNet study},
  url          = {http://dx.doi.org/10.3324/haematol.2019.239160},
  doi          = {10.3324/haematol.2019.239160},
  year         = {2020},
}